Rationally designed AAV2 and AAVrh8R capsids provide improved transduction in the retina and brain
The DOI matches its Crossref record; 56 of the 57 references it cites were found in a registry or an index.
Abstract
The successful application of adeno-associated virus (AAV) gene delivery vectors as a therapeutic paradigm will require efficient gene delivery to the appropriate cells in affected organs. In this study, we utilized a rational design approach to introduce modifications to the AAV2 and AAVrh8R capsids and the resulting variants were evaluated for transduction activity in the retina and brain. The modifications disrupted either capsid/receptor binding or altered capsid surface charge. Specifically, we mutated AAV2 amino acids R585A and R588A, which are required for binding to its receptor, heparan sulfate proteoglycans, to generate a variant referred to as AAV2-HBKO. In contrast to parental AAV2, the AAV2-HBKO vector displayed low-transduction activity following intravitreal delivery to the mouse eye; however, following its subretinal delivery, AAV2-HBKO resulted in significantly greater photoreceptor transduction. Intrastriatal delivery of AAV2-HBKO to mice facilitated widespread striatal and cortical expression, in contrast to the restricted transduction pattern of the parental AAV2 vector. Furthermore, we found that altering the surface charge on the AAVrh8R capsid by modifying the number of arginine residues on the capsid surface had a profound impact on subretinal transduction. The data further validate the potential of capsid engineering to improve AAV gene therapy vectors for clinical applications.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The VP3 VIII variable region of AAV2 has been shown to assist AAV2 in entering cells by recognizing the heparan sulfate proteoglycan (HSPG) site on the cell surface receptor43,55,56.”
From An adeno-associated virus variant enabling efficient ocular-directed gene delivery across species (2024) · cites this paper as [56]
Citations
Cites
Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145
Summerford, C., & Samulski, R. J. (1998) · Journal of Virology · doi:10.1128/jvi.72.2.1438-1445.1998 · Cited by 1,406
Xiao, X., Li, J., & Samulski, R. J. (1998) · Journal of Virology · doi:10.1128/jvi.72.3.2224-2232.1998 · Cited by 1,381
Hauswirth, W. W., Aleman, T. S., Kaushal, S., Cideciyan, A. V., Schwartz, S. B., Wang, L., Conlon, T. J., Boye, S. L., Flotte, T. R., Byrne, B. J., et al. (2008) · Human Gene Therapy · doi:10.1089/hum.2008.107 · Cited by 954
Rabinowitz, J. E., Rolling, F., Li, C., Conrath, H., Xiao, W., Xiao, X., & Samulski, R. J. (2002) · Journal of Virology · doi:10.1128/jvi.76.2.791-801.2002 · Cited by 762
Long-Term Effect of Gene Therapy on Leber’s Congenital Amaurosis
Bainbridge, J. W. B., Mehat, M. S., Sundaram, V., Robbie, S. J., Barker, S. E., Ripamonti, C., Georgiadis, A., Mowat, F. M., Beattie, S. G., Gardner, P. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414221 · Cited by 743
Burger, C., Gorbatyuk, O. S., Velardo, M. J., Peden, C. S., Williams, P., Zolotukhin, S., Reier, P. J., Mandel, R. J., & Muzyczka, N. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.05.024 · Cited by 741
Davidson, B. L., Stein, C. S., Heth, J. A., Martins, I., Kotin, R. M., Derksen, T. A., Zabner, J., Ghodsi, A., & Chiorini, J. A. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.7.3428 · Cited by 531
Cearley, C. N., & Wolfe, J. H. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2005.11.015 · Cited by 409
Identification of a heparin-binding motif on adeno-associated virus type 2 capsids
Kern, A., Schmidt, K., Leder, C., Müller, O. J., Wobus, C. E., Bettinger, K., Von der Lieth, C. W., King, J. A., & Kleinschmidt, J. A. (2003) · Journal of Virology · doi:10.1128/jvi.77.20.11072-11081.2003 · Cited by 380
Cited by
Adeno-Associated Virus Technologies and Methods for Targeted Neuronal Manipulation
Haery, L., Deverman, B. E., Matho, K. S., Cetin, A., Woodard, K., Cepko, C., Guerin, K. I., Rego, M. A., Ersing, I., Bachle, S. M., et al. (2019) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2019.00093 · Cited by 211
Adeno-Associated Virus Toolkit to Target Diverse Brain Cells
Challis, R. C., Ravindra Kumar, S., Chen, X., Goertsen, D., Coughlin, G. M., Hori, A. M., Chuapoco, M. R., Otis, T. S., Miles, T. F., & Gradinaru, V. (2022) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-111020-100834 · Cited by 148
“AAV2-HBKO, a modified AAV2 vector with enhanced cortical and striatal expression (Sullivan et al. 2018), shows neuron-biased transduction after intracranial injections in both mice (Sullivan et al. 2018) and macaques (Naidoo et al. 2018).”
BackgroundTargeting microglia with lentivirus and AAV: Recent advances and remaining challenges
Maes, M. E., Colombo, G., Schulz, R., & Siegert, S. (2019) · Neuroscience Letters · doi:10.1016/j.neulet.2019.134310 · Cited by 145
Peynshaert, K., Devoldere, J., Minnaert, A.-K., De Smedt, S. C., & Remaut, K. (2019) · Current Eye Research · doi:10.1080/02713683.2019.1565890 · Cited by 92
“saw that grafting of HSPG-binding residues on AAVs increased their accumulation at the ILM and augmented their transduction efficiencies,(51,52) while abolishing the HSPG-binding capability of AAV2 exceptionally reduced its effectivity.(51,53) Curiously, several serotypes (e.”
BackgroundWeiss, A., Liguore, W. A., Domire, J., Button, D., & McBride, J. (2020) · bioRxiv · doi:10.1038/s41598-020-63559-7 · Cited by 73
Metadata
- Authors
- Sullivan, J. A., Stanek, L. M., Lukason, M. J., Bu, J., Osmond, S. R., Barry, E. A., O’Riordan, C. R., Shihabuddin, L. S., Cheng, S. H., & Scaria, A.
- Corresponding author
- Sullivan, Jennifer A.
- Venue
- Gene Therapy
- Published
- 2018-05-22
- Volume
- 25
- Issue
- 3
- Pages
- 205-219
- ISSN
- 0969-7128 (ISSN-L)
- 1476-5462
- OpenAlex
- W2804837468
- Cited by
- 37
- References
- 57
- Citations by year
- 2026: 6 · 2025: 2 · 2024: 5 · 2023: 2 · 2022: 6 · 2021: 2 · 2020: 8 · 2019: 5 · 2018: 1
- FWCI
- 2.45
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Gene Therapy (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Sanofi
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Keywords
- adeno-associated virus vectors, AAV2, capsid engineering, arginine residues, retinal gene delivery, phototransduction, subretinal delivery, gene therapy vectors
- MeSH terms
- Dependovirus, Animals, Brain, Capsid, Genetic Vectors, HeLa Cells, Heparan Sulfate, Humans, Mice, Inbred C57BL, Photoreceptor Cells, Retina, Transduction, Genetic, Genetic Therapy, Gene Transfer Techniques, Parvovirinae, Capsid Proteins, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Rationally designed AAV2 and AAVrh8R capsids provide improved transduction in the retina and brain. https://app.cochat.ai/papers/10.1038/s41434-018-0017-8
- The paper
- Sullivan, J. A., Stanek, L. M., Lukason, M. J., Bu, J., Osmond, S. R., Barry, E. A., O’Riordan, C. R., Shihabuddin, L. S., Cheng, S. H., & Scaria, A. (2018). Rationally designed AAV2 and AAVrh8R capsids provide improved transduction in the retina and brain. Gene Therapy. https://doi.org/10.1038/s41434-018-0017-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.